PE20010490A1 - MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA - Google Patents

MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA

Info

Publication number
PE20010490A1
PE20010490A1 PE2000000804A PE0008042000A PE20010490A1 PE 20010490 A1 PE20010490 A1 PE 20010490A1 PE 2000000804 A PE2000000804 A PE 2000000804A PE 0008042000 A PE0008042000 A PE 0008042000A PE 20010490 A1 PE20010490 A1 PE 20010490A1
Authority
PE
Peru
Prior art keywords
mofetile
mycophenolate
ifn
peg
alpha
Prior art date
Application number
PE2000000804A
Other languages
Spanish (es)
Inventor
Friederike Zahm
Stephen Christopher Pappas
Mary Catherine Graves
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010490A1 publication Critical patent/PE20010490A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE AL USO DE INTERFERON ALFA 2A, UTILIZANDOSE DE 3-6 MILLONES DE UI ADMINISTRADAS TRES VECES POR SEMANA PARENTERALMENTE, INTERFERON ALFA 2A PEGILADO, UTILIZANDOSE DE 40 µg A 270 µg ADMINISTRADA UNA VEZ POR SEMANA PARENTERALMENTE ASOCIADO CON ACIDO MICOFENOLICO, UTILIZANDOSE DE 250mg/DIA A 2000mg/DIA ORALMENTE. LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDAD HEPATICA COMO INFECCIONES VIRALES, HEPATITIS CRONICA CIT REFERS TO THE USE OF INTERFERON ALFA 2A, USING 3-6 MILLION IU ADMINISTERED THREE TIMES PER WEEK PARENTERALLY, INTERFERON ALFA 2A PEGILATED, USING 40 µg TO 270 µg ADMINISTERED ONCE A WEEK OF MELTUALLY ASTILIZED ASTILIZED ASTILIZED 250mg. / DAY AT 2000mg / DAY ORALLY. THE COMBINATION MAY BE USEFUL FOR THE TREATMENT OF HEPATIC DISEASE SUCH AS VIRAL INFECTIONS, CHRONIC HEPATITIS C

PE2000000804A 1999-08-13 2000-08-08 MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA PE20010490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
PE20010490A1 true PE20010490A1 (en) 2001-04-27

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000804A PE20010490A1 (en) 1999-08-13 2000-08-08 MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA

Country Status (14)

Country Link
EP (1) EP1220683A2 (en)
JP (1) JP2003507339A (en)
CN (1) CN1368887A (en)
AU (1) AU7408200A (en)
BR (1) BR0013252A (en)
CA (1) CA2380653A1 (en)
HU (1) HUP0202525A3 (en)
MX (1) MXPA02001296A (en)
PE (1) PE20010490A1 (en)
PL (1) PL357367A1 (en)
RU (1) RU2002105485A (en)
TR (1) TR200200401T2 (en)
WO (1) WO2001012214A2 (en)
ZA (1) ZA200200280B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE476967T1 (en) * 2004-08-12 2010-08-15 Schering Corp STABLE PEGYLATED INTERFERON FORMULATION
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2016073825A1 (en) * 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
ZA200200280B (en) 2003-04-11
HUP0202525A3 (en) 2003-11-28
JP2003507339A (en) 2003-02-25
AU7408200A (en) 2001-03-13
BR0013252A (en) 2002-04-16
CN1368887A (en) 2002-09-11
TR200200401T2 (en) 2002-06-21
MXPA02001296A (en) 2002-07-22
RU2002105485A (en) 2004-01-27
WO2001012214A3 (en) 2001-10-04
HUP0202525A2 (en) 2002-11-28
CA2380653A1 (en) 2001-02-22
EP1220683A2 (en) 2002-07-10
PL357367A1 (en) 2004-07-26
WO2001012214A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
PE20010490A1 (en) MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA
PE20000560A1 (en) USE OF PEG-IFN-ALPHA AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
PE119199A1 (en) COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
ATE269321T1 (en) MEDICINAL PRODUCTS FOR VIRAL DISEASES
UY27069A1 (en) ISOINDOLIN-1-ONA TYPE GLUCOCINASE ACTIVATORS
PE72799A1 (en) MODIFIED POLYETHYLENE GLYCOL INTERFERONS
CL2008003939A1 (en) Use of escitalopram or a pharmaceutically acceptable salt thereof to prepare a drug useful in the treatment of social anxiety (divisional application 1799-00).
CL2012000421S1 (en) Illumination of isoscelic trapezoidal plan, triangular, convex and divergent upwards major lateral faces; the upper face has an isoscellic trapezoidal recess with beveled edges, and on the rear face, a "t" piece with a lower cylinder, the lower face has a wide isoscellic trapezoidal recess with curved sides.
BR9916027A (en) Glp-1 analogs
UY29868A1 (en) NUCLEOCIDOS 4 MODIFIED AS ANTIVIRAL AGENTS
PE20010284A1 (en) THE USE OF AN ANTIOXIDANT WITH RIBAVIRIN TO PREPARE A MEDICATION FOR THE TREATMENT OF A VIRAL INFECTION
MX9202374A (en) 1,3-OXATIOLANES USEFUL IN THE TREATMENT OF HEPATITIS.
ES2183093T3 (en) PREPARATION OF 1,1,1,3,3-PENTACLOROBUTAN AND 1,1,1,3,3-PENTAFLUORBUTAN.
ES2098723T3 (en) BEARING MATERIAL.
DK0758231T3 (en) Pharmaceutical preparations based on derivatives belonging to the taxane class
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
PA8587801A1 (en) POSITIONAL ISOMEROS OF INTERFERON ALFA 2-A MONOPEGILADO
AR057565A1 (en) ALFA AND C-FICOCIANINE INTERFERED FOR THE TREATMENT OF ALLERGIC AND CANCER AUOINMUNE DISEASES
AR061352A1 (en) THE USE OF TIMOSINA ALFA 1 TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF MALIGNOM MELANOMA OF STADIUM IV
PE20061079A1 (en) DEPSIPEPTIDES USEFUL IN THE PREVENTION OF VERTICAL INFECTIONS PRODUCED BY ENDOPARASITES
PE20001386A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA
BR0108997A (en) Adjuvant Immune Therapy for HIV
PE61699A1 (en) PHARMACEUTICAL COMPOSITION OF LAMIVUDINE
DE59105839D1 (en) LARGE WASHER.
AR029557A1 (en) COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF MASTITIS, AND USE OF OXAZOLIDINONE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF MASTITIS

Legal Events

Date Code Title Description
FD Application declared void or lapsed